9d
Zacks Investment Research on MSNHere's Why you Should Retain Nevro Stock in Your Portfolio NowNevro NVRO is well-poised for growth in the coming quarters, courtesy of its business expansion plans and restructuring ...
Nevro’s comprehensive HFXâ„¢ spinal cord stimulation (SCS) platform includes the Senza® SCS system and support services for the treatment of chronic pain of the trunk and limb and painful ...
23d
Zacks.com on MSNNevro Q4 Earnings & Revenues Beat Estimates, Gross Margin DownDuring the fourth quarter of 2024, Nevro made significant advancements in its product offerings and market expansion. The ...
REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO ), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results